Item 2.02 Results of Operations and Financial Condition.

On May 11, 2023, Sunshine Biopharma, Inc. (the "Company") issued a press release announcing the Company's financial results for the period ended March 31, 2023. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



99.1   Press Release

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).























  2

© Edgar Online, source Glimpses